Physician profile
Amar Anand
NPI 1407297005
$9,040.45
in general payments reported to CMS, 2019-2025
41 companies · $2,044 in 2025
The $2,044 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $557 · 2021: $900 · 2022: $2,040 · 2023: $1,776 · 2024: $1,528 · 2025: $2,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,346.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,389.29 | 2021-2025 | Ubrelvy, Duopa, Qulipta |
| Neurocrine Biosciences, INC. | $1,164.42 | 2022-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $1,017.68 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $655.17 | 2022-2025 | |
| Allergan, INC. | $524.42 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $464.49 | 2022 | |
| Lilly USA, LLC | $422.08 | 2021-2025 | Amyvid, Kisunla |
| Biogen, INC. | $376.69 | 2022-2025 | Vumerity, Tysabri, Skyclarys |
| Biohaven Pharmaceuticals, INC. | $334.03 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $329.65 | 2023-2025 | Rexulti, Nuedexta |
| Ucb, INC. | $298.33 | 2023-2025 | Briviact, Nayzilam, Fintepla |
| Neurelis, INC. | $211.44 | 2024-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $201.49 | 2021-2023 | Nuplazid |
| Celgene Corporation | $173.91 | 2022-2024 | Zeposia |
| Amgen INC. | $165.83 | 2021-2025 | Uplizna |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.